Overview
Atomwise utilizes a proprietary AI superplatform to explore the vast chemical space and identify novel, drug-like molecules for therapeutic applications. The platform employs deep convolutional neural networks trained on massive datasets of molecular structures and biological activities. It leverages structure-based drug design principles, predicting binding affinities between small molecules and target proteins. Atomwise's AI-driven approach accelerates the drug discovery process, reducing the time and cost associated with traditional methods. Use cases include identifying potential drug candidates for various diseases, repurposing existing drugs for new indications, and optimizing lead compounds for improved efficacy and safety. The platform particularly focuses on immune and inflammatory diseases, delivering programs with first- and best-in-class potential. The company consists of a world-class team of scientists and engineers.